A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Study ID
NCT07285902
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity

Key Dates

Start date
Dec 25, 2025
Status verified
Dec 2025
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
572 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group A: HRS9531 injection
  • Active Comparator: Treatment group B: Semaglutide Injection

Primary Outcome Measure

Percentage change from baseline in body weight after 52 weeks of treatment [ Time Frame: 52 weeks ]

Related Studies